Dr Neil Portman

Brown LJ; Achinger-Kawecka J; Portman N; Clark S; Stirzaker C; Lim E, 2022, 'Epigenetic Therapies and Biomarkers in Breast Cancer', Cancers, vol. 14, pp. 474 - 474, http://dx.doi.org/10.3390/cancers14030474

Portman N; Lim E, 2022, 'A new sophistication for breast cancer PDXs', Nature Cancer, vol. 3, pp. 138 - 140, http://dx.doi.org/10.1038/s43018-021-00328-z

Achinger-Kawecka J; Stirzaker C; Portman N; Campbell E; Chia K-M; Du Q; Laven-Law G; Nair SS; Yong A; Wilkinson A; Clifton S; Milioli HH; Alexandrou S; Caldon CE; Song J; Khoury A; Meyer B; Gee JMW; Schmitt A; Wong ES; Hickey TE; Lim E; Clark SJ, 2021, 'Epigenetic therapy targets the 3D epigenome in endocrine-resistant breast cancer', , http://dx.doi.org/10.1101/2021.06.21.449340

Alves CL; Ehmsen S; Terp MG; Portman N; Tuttolomondo M; Gammelgaard OL; Hundebøl MF; Kaminska K; Johansen LE; Bak M; Honeth G; Bosch A; Lim E; Ditzel HJ, 2021, 'Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer', Nature Communications, vol. 12, http://dx.doi.org/10.1038/s41467-021-25422-9

Alves CL; Ehmsen S; Terp MG; Portman N; Tuttolomondo M; Gammelgaard OL; Hundebøl MF; Kaminska K; Johansen LE; Bak M; Honeth G; Bosch A; Lim E; Ditzel HJ, 2021, 'Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer (Nature Communications, (2021), 12, 1, (5112), 10.1038/s41467-021-25422-9)', Nature Communications, vol. 12, pp. 5588, http://dx.doi.org/10.1038/s41467-021-25901-z

Aziz D; Portman N; Fernandez KJ; Lee C; Alexandrou S; Llop-Guevara A; Phan Z; Yong A; Wilkinson A; Sergio CM; Ferraro D; Etemadmoghadam D; Bowtell DD; Serra V; Waring P; Lim E; Caldon CE, 2021, 'Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition', npj Breast Cancer, vol. 7, http://dx.doi.org/10.1038/s41523-021-00312-x

Du Q; Smith GC; Luu PL; Ferguson JM; Armstrong NJ; Caldon CE; Campbell EM; Nair SS; Zotenko E; Gould CM; Buckley M; Chia KM; Portman N; Lim E; Kaczorowski D; Chan CL; Barton K; Deveson IW; Smith MA; Powell JE; Skvortsova K; Stirzaker C; Achinger-Kawecka J; Clark SJ, 2021, 'DNA methylation is required to maintain both DNA replication timing precision and 3D genome organization integrity', Cell Reports, vol. 36, http://dx.doi.org/10.1016/j.celrep.2021.109722

Freelander A; Brown LJ; Parker A; Segara D; Portman N; Lau B; Lim E, 2021, 'Molecular biomarkers for contemporary therapies in hormone receptor‐positive breast cancer', Genes, vol. 12, pp. 1 - 24, http://dx.doi.org/10.3390/genes12020285

Portman N; Chen J; Lim E, 2021, 'MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer', Frontiers in Oncology, vol. 11, http://dx.doi.org/10.3389/fonc.2021.777867

Chia KM; Freelander A; Kumar S; Parker A; Segara D; Portman N; Lim E, 2020, 'Estrogen receptor positive breast cancer patient–derived xenograft models in translational research', Current Opinion in Endocrine and Metabolic Research, vol. 15, pp. 31 - 36, http://dx.doi.org/10.1016/j.coemr.2020.10.004

Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E, 2020, 'MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer', Breast Cancer Research, vol. 22, pp. 87, http://dx.doi.org/10.1186/s13058-020-01318-2

Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E, 2020, 'MDM2 Inhibition in Combination with Endocrine Therapy and CDK4/6 Inhibition for the Treatment of ER-Positive Breast Cancer', , http://dx.doi.org/10.1101/2020.06.09.140921

Tadesse S; Anshabo AT; Portman N; Lim E; Tilley W; Caldon CE; Wang S, 2020, 'Targeting CDK2 in cancer: challenges and opportunities for therapy', Drug Discovery Today, vol. 25, pp. 406 - 413, http://dx.doi.org/10.1016/j.drudis.2019.12.001

Chia KM; Milioli H; Portman N; Laven-Law G; Coulson R; Yong A; Segara D; Parker A; Caldon CE; Deng N; Swarbrick A; Tilley WD; Hickey TE; Lim E, 2019, 'Non-canonical AR activity facilitates endocrine resistance in breast cancer', Endocrine-Related Cancer, vol. 26, pp. 251 - 264, http://dx.doi.org/10.1530/ERC-18-0333

Kennedy SP; Han JZR; Portman N; Nobis M; Hastings JF; Murphy KJ; Latham SL; Cadell AL; Miladinovic D; Marriott GR; O'Donnell YEI; Shearer RF; Williams JT; Munoz AG; Cox TR; Watkins DN; Saunders DN; Timpson P; Lim E; Kolch W; Croucher DR, 2019, 'Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer', Breast Cancer Research, vol. 21, pp. 43, http://dx.doi.org/10.1186/s13058-019-1127-y

MacEr-Wright JL; Stanley NR; Portman N; Tan JT; Bursill C; Rayner BS; Hawkins CL, 2019, 'A Role for Chlorinated Nucleosides in the Perturbation of Macrophage Function and Promotion of Inflammation', Chemical Research in Toxicology, vol. 32, pp. 1223 - 1234, http://dx.doi.org/10.1021/acs.chemrestox.9b00044

Portman N; Alexandrou S; Carson E; Wang S; Lim E; Caldon CE, 2019, 'Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer', Endocrine-Related Cancer, vol. 26, pp. R15 - R30, http://dx.doi.org/10.1530/ERC-18-0317

Varga V; Moreira-Leite F; Portman N; Gull K, 2017, 'Protein diversity in discrete structures at the distal tip of the trypanosome flagellum', PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 114, pp. E6546 - E6555, http://dx.doi.org/10.1073/pnas.1703553114

Lim E; Tarulli G; Portman N; Hickey TE; Tilley WD; Palmieri C, 2016, 'Pushing estrogen receptor around in breast cancer', Endocrine-Related Cancer, vol. 23, pp. T227 - T241, http://dx.doi.org/10.1530/ERC-16-0427

Foster C; Portman N; Chen M; Šlapeta J, 2014, 'Increased growth and pigment content of Chromera velia in mixotrophic culture', FEMS Microbiology Ecology, vol. 88, pp. 121 - 128, http://dx.doi.org/10.1111/1574-6941.12275

Portman N; Foster C; Walker G; Slapeta J, 2014, 'Evidence of Intraflagellar Transport and Apical Complex Formation in a Free-Living Relative of the Apicomplexa', EUKARYOTIC CELL, vol. 13, pp. 10 - 20, http://dx.doi.org/10.1128/EC.00155-13

Portman N; Gull K, 2014, 'Identification of Paralogous Life-Cycle Stage Specific Cytoskeletal Proteins in the Parasite Trypanosoma brucei', PLOS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0106777

Portman N; Slapeta J, 2014, 'The flagellar contribution to the apical complex: a new tool for the eukaryotic Swiss Army knife?', TRENDS IN PARASITOLOGY, vol. 30, pp. 58 - 64, http://dx.doi.org/10.1016/j.pt.2013.12.006

Portman N; Gull K, 2012, 'Proteomics and the Trypanosoma brucei cytoskeleton: advances and opportunities', PARASITOLOGY, vol. 139, pp. 1168 - 1177, http://dx.doi.org/10.1017/S0031182012000443

Portman N; Gull K, 2010, 'The paraflagellar rod of kinetoplastid parasites: From structure to components and function', INTERNATIONAL JOURNAL FOR PARASITOLOGY, vol. 40, pp. 135 - 148, http://dx.doi.org/10.1016/j.ijpara.2009.10.005

Hart SR; Lau KW; Hao Z; Broadhead R; Portman N; Huehmer A; Gull K; McKean PG; Hubbard SJ; Gaskell SJ, 2009, 'Analysis of the Trypanosome Flagellar Proteome Using a Combined Electron Transfer/Collisionally Activated Dissociation Strategy', JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, vol. 20, pp. 167 - 175, http://dx.doi.org/10.1016/j.jasms.2008.08.014

Lacomble S; Portman N; Gull K, 2009, 'A Protein-Protein Interaction Map of the Trypanosoma brucei Paraflagellar Rod', PLOS ONE, vol. 4, http://dx.doi.org/10.1371/journal.pone.0007685

Portman N; Lacomble S; Thomas B; McKean PG; Gull K, 2009, 'Combining RNA Interference Mutants and Comparative Proteomics to Identify Protein Components and Dependences in a Eukaryotic Flagellum', JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 284, pp. 5610 - 5619, http://dx.doi.org/10.1074/jbc.M808859200

Smith TK; Vasileva N; Gluenz E; Terry S; Portman N; Kramer S; Carrington M; Michaeli S; Gull K; Rudenko G, 2009, 'Blocking Variant Surface Glycoprotein Synthesis in Trypanosoma brucei Triggers a General Arrest in Translation Initiation', PLOS ONE, vol. 4, http://dx.doi.org/10.1371/journal.pone.0007532

Ginger ML; Portman N; McKean PG, 2008, 'Swimming with protists: perception, motility and flagellum assembly', NATURE REVIEWS MICROBIOLOGY, vol. 6, pp. 838 - 850, http://dx.doi.org/10.1038/nrmicro2009

Griffiths S; Portman N; Taylor PR; Gordon S; Ginger ML; Gull K, 2007, 'RNA interference mutant induction in vivo demonstrates the essential nature of trypanosome flagellar function during mammalian infection', EUKARYOTIC CELL, vol. 6, pp. 1248 - 1250, http://dx.doi.org/10.1128/EC.00110-07

Broadhead R; Dawe HR; Farr H; Griffiths S; Hart SR; Portman N; Shaw MK; Ginger ML; Gaskell SJ; McKean PG; Gull K, 2006, 'Flagellar motility is required for the viability of the bloodstream trypanosome', NATURE, vol. 440, pp. 224 - 227, http://dx.doi.org/10.1038/nature04541

Dawe HR; Farr H; Portman N; Shaw MK; Gull K, 2005, 'The Parkin co-regulated gene product, PACRG, is an evolutionarily conserved axonemal protein that functions in outer-doublet microtubule morphogenesis', JOURNAL OF CELL SCIENCE, vol. 118, pp. 5421 - 5430, http://dx.doi.org/10.1242/jcs.02659

Drewett V; Devitt A; Saxton J; Portman N; Greaney P; Cheong N; Alnemri TF; Alnemri E; Shaw PE, 2001, 'Serum response factor cleavage by caspases 3 and 7 linked to apoptosis in human BJAB cells', JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, pp. 33444 - 33451, http://dx.doi.org/10.1074/jbc.M103877200

Wahlroos S; Portman N; Bonder C; Hjorth M; Wilkinson A; Hastings J; Croucher D; Febbraio M; Gallego-Ortega D; Lim E, 2022, Exercise-induced modulation of the immune microenvironment in pre-clinical breast cancer models., http://dx.doi.org/10.21203/rs.3.rs-1789675/v1

Portman N; Milioli H; Alexandrou S; Coulson R; Yong A; Fernandez K; Chia K; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley W; Swarbrick A; Caldon L; Lim E, 2021, 'Abstract PS18-17: Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancer', in Cancer Research, American Association for Cancer Research (AACR), presented at Abstracts: 2020 San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020; San Antonio, Texas, http://dx.doi.org/10.1158/1538-7445.sabcs20-ps18-17

Portman N; Milioli H; Alexandrou S; Coulson R; Yong A; Fernandez K; Chia K; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley W; Swarbrick A; Caldon L; Lim E, 2021, 'Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 81, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000618737700638&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Aziz D; Portman N; Fernandez KJ; Lee C; Alexandrou S; Llop-Guevara A; Yong A; Wilkinson A; Sergio CM; Ferraro D; Etemadmoghadam D; Bowtell D; Investigators K; Serra V; Waring P; Lim E; Caldon CE, 2020, Cyclin E1 protein is stabilized in BRCA1 mutated breast cancers leading to synergy between CDK2 and PARP inhibitors, http://dx.doi.org/10.1101/2020.01.29.911883

Lim E; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia K; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon EC; Portman N, 2020, 'MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 110 - 110, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000790145400122&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Alexandrou S; Milioli HH; Portman N; Lee C; Fernandez K; Blake D; Lim E; Caldon L, 2019, 'S phase dysregulation occurs following resistance to CDK4/6 inhibition ER+ breast cancer', in Oncolabs, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P001

Chia KM; Milioli HH; Portman N; Laven-Law G; Coulson R; Young A; Segara D; Parker A; Caldon L; Deng N; Swarbrick A; Tilley W; Hickey T; Lim E, 2019, 'Targeting AR in endocrine-resistant breast cancer', in Oncolabs, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P012

Milioli HH; Chia KM; Portman N; Young A; Laven-Law G; Selth L; Tilley WD; Hickey T; Lim E, 2019, 'Androgen receptor activation in Endocrine-Resistant ER-positive breast cancer', in Oncolabs, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P034

Portman N; Milioli HH; Alexandrou S; Coulson R; Young A; Chia KM; Haup S; Haup Y; Caldon L; Lim E, 2019, 'The MDM2 inhibitor NVP-CGM097 synergises with fulvestrant and inhibits Estrogen Receptor positive breast cancer', presented at Hormone-Dependent Cancers (GRS), Newry, USA

Portman N; Milioli HH; Young A; Coulson R; Alexandrou S; Lam N; Haup S; Haup Y; Caldon L; Deng N; Lim E, 2019, 'Activation of p53 in combination with endocrine and CDK targeted therapies in ER+ breast cancer', in Oncolabs, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P043

Stirzaker C; Chia KM; Portman N; Milioli HH; Clifton S; Achinger-Kawecka J; Nair S; Lim E; Clark S, 2019, 'DNA demethylation agents as a therapeutic approach in endocrine-resistant breast cancer', in Oncolabs, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P049

Wahlroos S; Wilkinson A; Milioli H; Portman N; Gallego-Ortega D; Lim E, 2019, 'Concurrent exercise and chemotherapy in preclinical breast cancer models', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 80, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.SABCS19-P4-14-13

Chia KM; Milioli H; Portman N; Laven-Law G; Yong A; Swarbrick A; Caldon L; Tilley W; Hickey T; Lim E, 2018, 'Activation of AR inhibits growth of endocrine-resistant breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 79, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018, http://dx.doi.org/10.1158/1538-7445.SABCS18-P6-20-04

Lim E; Portman N; Alexandrou S; Haupt S; Haupt Y; Caldon E, 2018, 'Abstract P4-04-12: Therapeutic targeting of CDK4/6 inhibitor resistant breast cancer', in Cancer Research, American Association for Cancer Research (AACR), presented at Abstracts: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas, http://dx.doi.org/10.1158/1538-7445.sabcs17-p4-04-12

Lim E; Portman N; Alexandrou S; Haupt S; Haupt Y; Caldon E, 2017, 'Therapeutic targeting of CDK4/6 inhibitor resistant breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 78, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 05 December 2017 - 09 December 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000425489401175&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1